A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo

Aaron Petty, Eugene Myshkin, Haina Qin, Hong Guo, Hui Miao, Gregory P. Tochtrop, Jer Tsong Hsieh, Phillip Page, Lili Liu, Daniel J. Lindner, Chayan Acharya, Alexander D. MacKerell, Eckhard Ficker, Jianxing Song, Bingcheng Wang

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

During tumor progression, EphA2 receptor can gain ligand-independent pro-oncogenic functions due to Akt activation and reduced ephrin-A ligand engagement. The effects can be reversed by ligand stimulation, which triggers the intrinsic tumor suppressive signaling pathways of EphA2 including inhibition of PI3/Akt and Ras/ERK pathways. These observations argue for development of small molecule agonists for EphA2 as potential tumor intervention agents. Through virtual screening and cell-based assays, we report here the identification and characterization of doxazosin as a novel small molecule agonist for EphA2 and EphA4, but not for other Eph receptors tested. NMR studies revealed extensive contacts of doxazosin with EphA2/A4, recapitulating both hydrophobic and electrostatic interactions recently found in the EphA2/ephrin-A1 complex. Clinically used as an α1-adrenoreceptor antagonist (Cardura®) for treating hypertension and benign prostate hyperplasia, doxazosin activated EphA2 independent of α1-adrenoreceptor. Similar to ephrin-A1, doxazosin inhibited Akt and ERK kinase activities in an EphA2-dependent manner. Treatment with doxazosin triggered EphA2 receptor internalization, and suppressed haptotactic and chemotactic migration of prostate cancer, breast cancer, and glioma cells. Moreover, in an orthotopic xenograft model, doxazosin reduced distal metastasis of human prostate cancer cells and prolonged survival in recipient mice. To our knowledge, doxazosin is the first small molecule agonist of a receptor tyrosine kinase that is capable of inhibiting malignant behaviors in vitro and in vivo.

Original languageEnglish (US)
Article numbere42120
JournalPLoS One
Volume7
Issue number8
DOIs
StatePublished - Aug 15 2012

Fingerprint

EphA2 Receptor
Doxazosin
prostatic neoplasms
cell movement
metastasis
agonists
Cell Movement
tyrosine
Tumors
Prostatic Neoplasms
phosphotransferases (kinases)
Cells
Neoplasm Metastasis
mitogen-activated protein kinase
receptors
Molecules
neoplasms
receptor protein-tyrosine kinase
Ephrin-A1
Neoplasms

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. / Petty, Aaron; Myshkin, Eugene; Qin, Haina; Guo, Hong; Miao, Hui; Tochtrop, Gregory P.; Hsieh, Jer Tsong; Page, Phillip; Liu, Lili; Lindner, Daniel J.; Acharya, Chayan; MacKerell, Alexander D.; Ficker, Eckhard; Song, Jianxing; Wang, Bingcheng.

In: PLoS One, Vol. 7, No. 8, e42120, 15.08.2012.

Research output: Contribution to journalArticle

Petty, A, Myshkin, E, Qin, H, Guo, H, Miao, H, Tochtrop, GP, Hsieh, JT, Page, P, Liu, L, Lindner, DJ, Acharya, C, MacKerell, AD, Ficker, E, Song, J & Wang, B 2012, 'A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo', PLoS One, vol. 7, no. 8, e42120. https://doi.org/10.1371/journal.pone.0042120
Petty, Aaron ; Myshkin, Eugene ; Qin, Haina ; Guo, Hong ; Miao, Hui ; Tochtrop, Gregory P. ; Hsieh, Jer Tsong ; Page, Phillip ; Liu, Lili ; Lindner, Daniel J. ; Acharya, Chayan ; MacKerell, Alexander D. ; Ficker, Eckhard ; Song, Jianxing ; Wang, Bingcheng. / A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. In: PLoS One. 2012 ; Vol. 7, No. 8.
@article{b5f396f5ddb945c9a8014374df464725,
title = "A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo",
abstract = "During tumor progression, EphA2 receptor can gain ligand-independent pro-oncogenic functions due to Akt activation and reduced ephrin-A ligand engagement. The effects can be reversed by ligand stimulation, which triggers the intrinsic tumor suppressive signaling pathways of EphA2 including inhibition of PI3/Akt and Ras/ERK pathways. These observations argue for development of small molecule agonists for EphA2 as potential tumor intervention agents. Through virtual screening and cell-based assays, we report here the identification and characterization of doxazosin as a novel small molecule agonist for EphA2 and EphA4, but not for other Eph receptors tested. NMR studies revealed extensive contacts of doxazosin with EphA2/A4, recapitulating both hydrophobic and electrostatic interactions recently found in the EphA2/ephrin-A1 complex. Clinically used as an α1-adrenoreceptor antagonist (Cardura{\circledR}) for treating hypertension and benign prostate hyperplasia, doxazosin activated EphA2 independent of α1-adrenoreceptor. Similar to ephrin-A1, doxazosin inhibited Akt and ERK kinase activities in an EphA2-dependent manner. Treatment with doxazosin triggered EphA2 receptor internalization, and suppressed haptotactic and chemotactic migration of prostate cancer, breast cancer, and glioma cells. Moreover, in an orthotopic xenograft model, doxazosin reduced distal metastasis of human prostate cancer cells and prolonged survival in recipient mice. To our knowledge, doxazosin is the first small molecule agonist of a receptor tyrosine kinase that is capable of inhibiting malignant behaviors in vitro and in vivo.",
author = "Aaron Petty and Eugene Myshkin and Haina Qin and Hong Guo and Hui Miao and Tochtrop, {Gregory P.} and Hsieh, {Jer Tsong} and Phillip Page and Lili Liu and Lindner, {Daniel J.} and Chayan Acharya and MacKerell, {Alexander D.} and Eckhard Ficker and Jianxing Song and Bingcheng Wang",
year = "2012",
month = "8",
day = "15",
doi = "10.1371/journal.pone.0042120",
language = "English (US)",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo

AU - Petty, Aaron

AU - Myshkin, Eugene

AU - Qin, Haina

AU - Guo, Hong

AU - Miao, Hui

AU - Tochtrop, Gregory P.

AU - Hsieh, Jer Tsong

AU - Page, Phillip

AU - Liu, Lili

AU - Lindner, Daniel J.

AU - Acharya, Chayan

AU - MacKerell, Alexander D.

AU - Ficker, Eckhard

AU - Song, Jianxing

AU - Wang, Bingcheng

PY - 2012/8/15

Y1 - 2012/8/15

N2 - During tumor progression, EphA2 receptor can gain ligand-independent pro-oncogenic functions due to Akt activation and reduced ephrin-A ligand engagement. The effects can be reversed by ligand stimulation, which triggers the intrinsic tumor suppressive signaling pathways of EphA2 including inhibition of PI3/Akt and Ras/ERK pathways. These observations argue for development of small molecule agonists for EphA2 as potential tumor intervention agents. Through virtual screening and cell-based assays, we report here the identification and characterization of doxazosin as a novel small molecule agonist for EphA2 and EphA4, but not for other Eph receptors tested. NMR studies revealed extensive contacts of doxazosin with EphA2/A4, recapitulating both hydrophobic and electrostatic interactions recently found in the EphA2/ephrin-A1 complex. Clinically used as an α1-adrenoreceptor antagonist (Cardura®) for treating hypertension and benign prostate hyperplasia, doxazosin activated EphA2 independent of α1-adrenoreceptor. Similar to ephrin-A1, doxazosin inhibited Akt and ERK kinase activities in an EphA2-dependent manner. Treatment with doxazosin triggered EphA2 receptor internalization, and suppressed haptotactic and chemotactic migration of prostate cancer, breast cancer, and glioma cells. Moreover, in an orthotopic xenograft model, doxazosin reduced distal metastasis of human prostate cancer cells and prolonged survival in recipient mice. To our knowledge, doxazosin is the first small molecule agonist of a receptor tyrosine kinase that is capable of inhibiting malignant behaviors in vitro and in vivo.

AB - During tumor progression, EphA2 receptor can gain ligand-independent pro-oncogenic functions due to Akt activation and reduced ephrin-A ligand engagement. The effects can be reversed by ligand stimulation, which triggers the intrinsic tumor suppressive signaling pathways of EphA2 including inhibition of PI3/Akt and Ras/ERK pathways. These observations argue for development of small molecule agonists for EphA2 as potential tumor intervention agents. Through virtual screening and cell-based assays, we report here the identification and characterization of doxazosin as a novel small molecule agonist for EphA2 and EphA4, but not for other Eph receptors tested. NMR studies revealed extensive contacts of doxazosin with EphA2/A4, recapitulating both hydrophobic and electrostatic interactions recently found in the EphA2/ephrin-A1 complex. Clinically used as an α1-adrenoreceptor antagonist (Cardura®) for treating hypertension and benign prostate hyperplasia, doxazosin activated EphA2 independent of α1-adrenoreceptor. Similar to ephrin-A1, doxazosin inhibited Akt and ERK kinase activities in an EphA2-dependent manner. Treatment with doxazosin triggered EphA2 receptor internalization, and suppressed haptotactic and chemotactic migration of prostate cancer, breast cancer, and glioma cells. Moreover, in an orthotopic xenograft model, doxazosin reduced distal metastasis of human prostate cancer cells and prolonged survival in recipient mice. To our knowledge, doxazosin is the first small molecule agonist of a receptor tyrosine kinase that is capable of inhibiting malignant behaviors in vitro and in vivo.

UR - http://www.scopus.com/inward/record.url?scp=84865050506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865050506&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0042120

DO - 10.1371/journal.pone.0042120

M3 - Article

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - e42120

ER -